








Article

Pre-Diagnosis Diet Predicts Response to Exclusive Enteral Nutrition and Correlates with Microbiome in Pediatric Crohn Disease

Stephanie Dijk ¹, Megan Jarman ², Zhengxiao Zhang ^{3,4}, Morgan Lawley ⁵, Muzammil Ahmad ⁵, Ricardo Suarez ⁵, Laura Rossi ⁶, Min Chen ⁷, Jessica Wu ⁷, Matthew W. Carroll ⁵, Anthony Otley ⁸, Mary Sherlock ⁹, David R. Mack ¹⁰, Kevan Jacobson ¹¹, Jennifer C. deBruyn ¹², Wael El-Matary ¹³, Colette Deslandres ¹⁴, Mohsin Rashid ⁸, Peter C. Church ¹⁵, Thomas D. Walters ¹⁵, Hien Q. Huynh ⁵, Michael G. Surette ^{6,16}, Anne M. Griffiths ¹⁵ and Eytan Wine ^{1,5,*} on behalf of the Canadian Children IBD Network

- ¹ Department of Physiology, University of Alberta, Edmonton, AB T6G 1C9, Canada
 - ² Department of Agriculture, Life, & Environmental Science, University of Alberta, Edmonton, AB T6G 2R3, Canada; m.jarman@aston.ac.uk
 - ³ Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada; zxzhang@jmu.edu.cn
 - ⁴ College of Food and Biological Engineering, Jimei University, Xiamen 361000, China
 - ⁵ Division of Pediatric Gastroenterology, Department of Pediatrics, University of Alberta, Edmonton, AB T6G 2R3, Canada; mahmad1@ualberta.ca (M.A.); suarez@ualberta.ca (R.S.); mcarroll@ualberta.ca (M.W.C.); hien.huynh@ualberta.ca (H.Q.H.)
 - ⁶ Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON L8S 4L8, Canada; rossil@mcmaster.ca (L.R.); surette@mcmaster.ca (M.G.S.)
 - ⁷ Nutrition Services (Child Health), Alberta Health Services, Edmonton, AB T5J 3E4, Canada; min.chen@albertahealthservices.ca (M.C.); jessica.wu@albertahealthservices.ca (J.W.)
 - ⁸ Division of Gastroenterology & Nutrition, Department of Pediatrics, Dalhousie University, Halifax, NS B3H 4R2, Canada; arotley@dal.ca (A.O.); mohsin.rashid@iwbk.nshealth.ca (M.R.)
 - ⁹ Division of Gastroenterology and Nutrition, Department of Pediatrics, McMaster University, Hamilton, ON L8S 4L8, Canada; sherlom@mcmaster.ca
 - ¹⁰ CHEO IBD Center, Department of Pediatrics, University of Ottawa, Ottawa, ON K1N 6N5, Canada
 - ¹¹ Division of Gastroenterology, Hepatology and Nutrition, B.C. Children's Hospital, British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada; kjacobson@cw.bc.ca
 - ¹² Section of Pediatric Gastroenterology, Department of Pediatrics, University of Calgary, Calgary, AB T2N 1N4, Canada; jennifer.debruyn@albertahealthservices.ca
 - ¹³ Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; welmatary@hsc.mb.ca
 - ¹⁴ Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, CHU Sainte-Justine Hospital, Université de Montréal, Montréal, QC H3T 1J4, Canada; colette.deslandres@umontreal.ca
 - ¹⁵ Division of Pediatric Gastroenterology, IBD Center, Hospital for Sick Children, University of Toronto, Toronto, ON M5S 1C6, Canada; peter.church@sickkids.ca (P.C.C.); thomas.walters@sickkids.ca (T.D.W.); anne.griffiths@sickkids.ca (A.M.G.)
 - ¹⁶ Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON L8S 4L8, Canada
- * Correspondence: wine@ualberta.ca; Tel.: +1-780-248-5420



Citation: Dijk, S.; Jarman, M.; Zhang, Z.; Lawley, M.; Ahmad, M.; Suarez, R.; Rossi, L.; Chen, M.; Wu, J.; Carroll, M.W.; et al. Pre-Diagnosis Diet Predicts Response to Exclusive Enteral Nutrition and Correlates with Microbiome in Pediatric Crohn Disease. *Nutrients* **2024**, *16*, 1033. <https://doi.org/10.3390/nu16071033>

Academic Editor: Roberto De Giorgio

Received: 9 March 2024

Revised: 26 March 2024

Accepted: 29 March 2024

Published: 2 April 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Exclusive enteral nutrition (EEN) is effective in inducing remission in pediatric Crohn disease (CD). EEN alters the intestinal microbiome, but precise mechanisms are unknown. We hypothesized that pre-diagnosis diet establishes a baseline gut microbiome, which then mediates response to EEN. We analyzed prospectively recorded food frequency questionnaires (FFQs) for pre-diagnosis dietary patterns. Fecal microbiota were sequenced (16SrRNA) at baseline and through an 18-month follow-up period. Dietary patterns, Mediterranean diet adherence, and stool microbiota were associated with EEN treatment outcomes, disease flare, need for anti-tumor necrosis factor (TNF)- α therapy, and long-term clinical outcomes. Ninety-eight patients were included. Baseline disease severity and microbiota were associated with diet. Four dietary patterns were identified by FFQs; a “mature diet” high in fruits, vegetables, and fish was linked to increased baseline microbial diversity, which was associated with fewer disease flares ($p < 0.05$) and a trend towards a delayed need for anti-TNF therapy ($p = 0.086$). Baseline stool microbial taxa were increased (*Blautia* and

Faecalibacterium) or decreased (*Ruminococcus gnavus* group) with the mature diet compared to other diets. Surprisingly, a “pre-packaged” dietary pattern (rich in processed foods) was associated with delayed flares in males ($p < 0.05$). Long-term pre-diagnosis diet was associated with outcomes of EEN therapy in pediatric CD; diet–microbiota and microbiota–outcome associations may mediate this relationship.

Keywords: pediatrics; inflammatory bowel diseases; nutrition; microbiome; dietary pattern; prediction

1. Introduction

The worldwide incidence of inflammatory bowel diseases (IBDs) is increasing, especially in children [1]. Pediatric IBD can result in linear growth failure, delayed puberty, and reduced peak bone density [2]. The poorly understood etiology includes altered immune system, environment, gene, and gut microbiome interactions [3,4]. Diet, an important component of the gut environment, is one of the main determinants of the intestinal microbiome [5], which is significantly altered in IBD [6]. Diet is known to affect the risk of IBD development or flare [7,8] and is thought to exert effects through altering host immunity, intestinal barrier integrity, and microbiota [7].

A Mediterranean diet (MED) high in vegetables, fruits, cereals, and olive oil can reduce disease activity in both forms of IBD—Crohn disease (CD) and ulcerative colitis (UC) [9,10]. The MED increases microbial taxa associated with health, such as *Faecalibacterium prausnitzii* and *Roseburia* spp. [11]; both of these are reduced in IBD [6]. Mediterranean and other dietary-fiber-rich diets can reduce the risk of host intestinal mucus layer depletion by microbes, compromising intestinal barrier integrity and increasing immune activation [7].

Exclusive enteral nutrition (EEN) entails 6–8 weeks of liquid meal replacement with the exclusion of all other food and is a first-line therapy for mild to moderate CD [12]. EEN is more effective than glucocorticoids (GCSs) for achieving mucosal healing, inducing remission in up to 80% of patients while sparing GCS-associated side effects in children [13]. Excluding offending dietary agents, immune and/or microbial modulation, and improved intestinal barrier by decreasing inflammation are thought to explain the mechanisms of EEN action [14]. Detecting the predictors of response to EEN can help elucidate mechanisms, identify diet therapy candidates, and improve current treatments, which is especially important given challenges with EEN therapy such as taste fatigue, tolerability, and significant costs [15].

EEN-induced microbial shifts differ between therapy responders and non-responders [16] and may impact therapy response. Previously, long-term diet was identified in animal studies to predict microbial shifts in response to dietary therapy [17]. Given the stability of the microbiome despite changes in response to short-term dietary alterations and the ability for baseline microbiota to predict response to EEN [16], the microbiome established in response to a patient’s long-term diet may play a role in mediating the response to subsequent EEN therapy [18]. This is supported by models where the gut microbiome is identified as more important than the food itself for predicting clinical outcomes to foods such as glycemic response [19]. As diet is a modifiable factor, showing a predictive role can positively and safely impact treatment outcomes for patients with IBD. We therefore hypothesized that in pediatric patients with CD, pre-diagnosis long-term dietary patterns may predict responses to EEN, mediated through the intestinal microbiome.

2. Materials and Methods

2.1. Setting and Participants

The Canadian Children Inflammatory Bowel Disease Network (CIDCaNN; <https://cidscann.ca/> (accessed on 28 March 2024)) prospectively enrolled and followed new-onset pediatric IBD cases until transition to adult services, as previously described [20]. Comprehensive baseline phenotypic and longitudinal disease activity assessments, labora-

tory parameters, and therapy details were collected prospectively at ad hoc and routine six-month periodic reviews using standardized case report forms (CRFs) and documented on REDCap [21]. IBD-focused pediatric gastroenterologists approved the diagnostic IBD label using conventional clinical, endoscopic, and histologic criteria according to the Paris classification [22], with disease location based on macroscopic findings observed via colonoscopy and MR enterography. Endoscopic findings were documented using the Simple Endoscopic Score for CD (SES-CD).

2.2. Patient and Public Engagement

Patients/caregivers of pediatric IBD patients and other stakeholders have identified their most important research questions; their third priority research question was, “What role does diet have in the management of pediatric IBD?” [23]. These priorities have informed our research directions and hypothesis.

2.3. Study Design

This was an open-label prospective study within CIDsCANN. Eligible children were newly diagnosed with CD and enrolled between February 2014 and June 2017, treated with EEN as a first induction therapy, and completed food frequency questionnaires (FFQs, reflecting the year prior to diagnosis) within 90 days of diagnosis. From the national cohort of ~1500 children newly diagnosed with IBD, 942 had CD (following the Porto criteria) [24]; 103 of these patients met the eligibility criteria by having an FFQ available and receiving EEN as their primary induction therapy. Parents completed FFQs for younger children as needed. Patients from 10 pediatric centers across Canada met the inclusion criteria (Table S1). Informed consent/assent was obtained from parents/patients, and participants were free to withdraw at any time. Ethics approval was obtained at each participating center (University of Alberta Ethics ID#: Pro00042980).

Fecal calprotectin (FCP) was measured by locally validated ELISA at baseline, 2, 12, and 18 months (Table S2). Clinical outcomes were collected every 6 months for 18 months following EEN initiation.

The FFQ was previously validated in Canadian pediatric and adolescent populations and assessed dietary intakes over the previous 12 months [25]. Dietary pattern analysis was conducted using principal component (PC) analysis (PCA) on kilocalorie-adjusted food groups (Table S3); the obtained PCs were used to identify dietary patterns that maximally captured dietary variability within our study population. These data-derived diet patterns capture correlated food consumptions within our study population and are named for the food themes that most characterize each pattern (see further details in the Supplemental Materials). Patient scores for each PC reflected their relative adherence to each dietary pattern (for each patient, an adherence value for each of the four patterns was obtained). Importantly, each patient included in the study had a calculated rate of adherence (defined relative to the entire study population) to each of the dietary patterns identified, and each individual was highly or poorly adherent to more than one diet. To assess associations with an MED, we used a tertile-defined scoring system to calculate a relative MED (rMED) score for each patient. Established by Buckland et al. [26] based on Trichopoulou et al. [27], 1–3 points were assigned reflecting relative tertiles of intake after calorie adjustment by the Willett residuals method (referenced and summarized in the Supplemental Materials). To calculate rMED scores, three points were assigned to patients in the highest tertiles of vegetables, fruits, nuts, legumes, fish, cereals, and red wine, as well as those in the lowest tertiles for consumption of high-fat dairy and meat. Two and one points were assigned to the declining tertiles, respectively.

2.4. Clinical Outcomes of Interest

Clinical features, including weighted pediatric CD activity index (wPCDAI) and physician global assessment (PGA) [28], were recorded at baseline and every 6 months. Failure of EEN was defined as the need for therapy with either monoclonal anti-tumor

necrosis factor (TNF)- α antibodies (mostly infliximab) or systemic GCS therapy prior to completing 60 days of EEN. Therapy decisions were not protocolized but rather determined by the treating physician. Reasons for stopping EEN were individually reviewed (by SD and EW), based on systematic data entry; failures were sub-classified into “lack of response” (replaced EEN therapy within 14 days) or “loss of response” (replaced EEN after 14–60 days). Survival time until disease flare or need for treatment escalation were defined by a need for GCS/anti-TNF, respectively, after successful EEN. A reason for stopping cited as “patient choice” was classified as intolerance of EEN (considered neither response nor failure). Administration of immunomodulators (methotrexate; azathioprine) or anti-TNF as pre-planned maintenance therapy at any time point was recorded but not defined as failure. SES-CD [29] was obtained at diagnosis and used as a baseline indicator of disease activity. Disease location, defined by the Paris classification, was categorized as ileal CD (Paris L1) or colonic/ileocolonic CD (Paris L2/L3); due to small numbers, L4 was not specified [22]. Improvement in PGA was defined as any reduction in PGA by six months.

2.5. Fecal Microbiome 16s rRNA Sequencing Analysis

Stool specimens were collected and frozen immediately in the patient’s freezer, transported on ice, and stored at -80 ± 10 °C. Bacterial DNA was extracted from an aliquot (two to three punch biopsies from frozen stool; 0.18–0.22 g) of fecal samples as described previously and sequenced with minor modifications [30]. Bioinformatics was completed using the QIIME2 [31] pipeline with DADA2 [32], generating amplicon sequence variants (ASV) used for further statistical analysis. DNA extraction, sequencing, and bioinformatics are further described in the Supplemental Materials.

2.6. Statistical Analysis

Dietary patterns resulting from dimensionality reduction of dietary data by PCA and rMED scores were correlated with clinical features such as age, sex, disease location, post-treatment six-month wPCDAI [33], and PGA scores. Mann–Whitney U tests, Kruskal–Wallis tests, and Spearman correlations were completed using Stata 14 (Stata Statistical Software: Release 14. StataCorp LP, College Station, TX, USA) [34]. Multivariable COX proportional hazard regression survival analysis of time to anti-TNF or disease flare was performed using Stata 14 [34], with patients censored at their last recorded appointment if <18 months of follow-up. Sex, disease location, and perianal disease showed no significant interactions ($p > 0.1$) and so were not included in the model. When assessing six-month height Z-scores, patients taking GCS prior to their six-month follow-up were excluded. Simpson and Shannon diversity and Chao1 richness were calculated using ASV-level microbial data. Data were visualized using GraphPad Prism version 9.1.2 for Windows (GraphPad Software, San Diego, CA, USA; www.graphpad.com).

3. Results

3.1. Patient Clinical Characteristics

One hundred and three patients met the inclusion criteria (EEN induction therapy and completed FFQ within a mean of 24 days) with complete baseline data (Figure 1A); eligible patients were diagnosed February 2014–March 2017. Five patients concomitantly beginning anti-TNF induction therapy were excluded, leaving 98 patients with a median of 518 days of follow-up [interquartile range (IQR) 109]. Twelve (12%) patients failed EEN induction therapy (required GCS or unplanned anti-TNF therapy within 60 days), four of whom had a lack of response (4%, failure <14 days), while eight had a loss of response (8%, failure 14–60 days). Seventeen patients (17%) experienced disease flare (required GCS) during the 18 months of follow-up, four of whom also met the criteria for EEN failure (included in both groups). Two patients (2%) were intolerant of EEN. Seventy-six (76%) patients successfully completed EEN induction therapy and did not experience a disease flare during follow-up; however, 48/76 (63%) EEN responders were initiated on anti-TNF maintenance therapy

during follow-up. Overall, 40 out of 103 (39%) patients were on anti-TNF maintenance therapy by six months, and 79 (77%) were on immunomodulators.




Figure 1. Patient characteristics and major outcomes. **(A):** Flowchart of patient numbers throughout inclusion and outcome criteria. After exclusion, 98 patients were included in the analysis, of whom 76 did not require steroids, but 48 of those were initiated on anti-TNF therapy during maintenance. EEN = exclusive enteral nutrition, 5ASA = 5-aminosalicylate, anti-TNF = anti-tumor necrosis factor- α , GCS = glucocorticoid. **(B):** Baseline clinical characteristics of 103 patients included in the study. **(C):** Physician global assessment (PGA) was available for 48 patients at baseline and 6 months; PGA improved from baseline to 6 months follow-up. **(D):** Fecal calprotectin (FCP) tended to decrease from baseline to 2 months for the eight patient responders with paired specimens. **** = $p < 0.0001$.

The mean age at enrollment and diagnosis was 12.5 years (standard deviation: 2.8 y), with no significant difference between males and females ($p > 0.5$; Figure 1B). No difference in disease location or complicated disease were seen between males and females, and 96% had uncomplicated inflammatory disease (Paris B1). Forty-eight patients had a six-month PGA available and had not required GCS or anti-TNF (used to assess long-term disease activity in response to EEN therapy), showing significant improvement (Figure 1C). wPCDAI was only available for 23 patients at six months, with 22 baseline and six-month pairs. wPCDAI in this small subset was not associated with clinical outcomes of interest or microbiota. Baseline SES-CD score was available for 89 patients.

A total of 36 patients (37%) provided stool for 16S analysis at baseline (prior to starting therapy) and 24 at six months, with 18 pairs. Sixteen and fourteen stool specimens for 16S were collected at 12 and 18 months, respectively (Table S2). FCP was available at baseline for 29 patients and after two months for 13 patients, with nine pairs. There was a trending decrease in FCP in those eight patients with successful EEN induction ($p = 0.055$, $n = 8$; Figure 1D).

3.2. Dietary Pattern Associations with Patient Features

Dietary Pattern Analysis

Adjusted servings were used to conduct PCA that was orthogonally rotated to minimize correlation between the different dietary factors. Patient scores for each PC were converted into Z-scores for correlation with clinical outcomes. Z-scores greater than 3 or less than -3 were deemed outliers and were excluded from further analysis. A cut off of four PCs/dietary patterns was used based on eigenvalues (Table S4). Dietary factor loadings > 0.2 were considered of importance in the first four PCs and used to characterize and name the dietary patterns (Table 1). Of note, each individual included in the study will have a value of adherence to each of the four identified dietary patterns.

Four dietary patterns (PAs) had eigenvalues > 3 , and each accounted for $>7\%$ of dietary variability (Table S4). Food groups with high factor loadings that characterized each pattern are summarized in Table 1. Food groups with positive correlations (factor loadings) had increased consumption with increased adherence to the pattern, while food groups with negative correlations had decreased consumption with increased adherence to the pattern. The “vegetarian” pattern was characterized by high consumption of whole grains, vegetable soup, soy and tofu products, salad dressing, fruit, full-fat dairy, and butter, with relatively low intakes of fried or skin-on chicken or turkey. The “meat” food pattern included more rice products, non-vegetable soups, and both red and non-red meats, with relatively low intakes of unfried or skin-off chicken or turkey and granola bars. “Pre-packaged” had high intakes of high-fiber cereals, sugary condiments, breaded fish, and diet soda, with relatively low intakes of processed and lean red meat. Finally, the “mature” pattern had relatively high intakes of unfried or skin-off chicken or turkey, fish, seafood, vegetables, fruit, coffee, alcohol, and milk alternatives, with a relatively low intake of pizza.

rMED scores were positively associated with vegetarian and mature diet adherence ($\rho = 0.2035$, $p < 0.05$; $\rho = 0.5989$, $p < 0.0001$, respectively) and had a trending positive association with adherence to a pre-packaged pattern ($\rho = 0.1907$, $p = 0.0537$; Figure S1). Age was positively associated with mature diet adherence ($\rho = 0.3586$, $p < 0.001$; Figure S2). Mature diet adherence and rMED score were negatively associated with SES-CD score in females ($n = 37$, $\rho = -0.42$, $p < 0.05$; $\rho = -0.4406$, $p < 0.01$, respectively); mature diet adherence was also negatively associated with baseline FCP in males ($\rho = -0.4556$, $p < 0.05$, $n = 20$) (Figure 2A–C).

Table 1. Main features of identified dietary patterns.

Dietary Pattern:	“Vegetarian”	“Meat”	“Pre-Packaged”	“Mature”
Food Groups Positively Associated (factor loading)	Whole Grains 0.3048	Rice, Rice Noodles, Couscous 0.2887	High-Fiber Cereals 0.3944	Chicken, Turkey without skin/fried 0.207
	Vegetable Soup 0.3134	Other Soups 0.4105	Sugary Condiments 0.2856	Fish 0.2581
	Soy/Tofu 0.3047	Red Meat 0.277	Breaded Fish 0.3549	Seafood 0.2148
	Salad Dressing 0.2733	Pork 0.3495	Diet Soda 0.4256	Vegetables 0.3751
	Fruit 0.2103	Liver Organs 0.2043		Fruit 0.2546
	Full-Fat Dairy 0.2678	Chicken, Turkey with skin or fried 0.3161		Coffee 0.2245
	Butter 0.2973			Alcohol 0.2503 Milk Alternatives 0.2153
Food Groups Negatively Associated (factor loading)	Chicken, Turkey with skin or fried −0.222	Chicken, Turkey without skin/fried −0.2104	Lean Red Meat −0.2424	Pizza −0.3615
		Granola Bars −0.2191	Processed Meat −0.2182	

Dietary patterns obtained as the first four principal components from FFQ PCA analysis. Food groups and their factor loadings (representing the relative contribution of each food group to the dietary pattern) are shown. Green shading represents food groups with a positive association with dietary adherence scores; red shading indicates food groups with a negative association with dietary adherence scores.

3.3. Dietary Pattern Associations with Clinical Outcomes

Males exhibiting a loss of clinical response to EEN had significantly higher meat diet adherence ($n = 4$, median 0.82, vs. responders $n = 51$, median -0.17 , IQR -0.57 – 0.38 ; Figure 2E, $p < 0.05$). Males with higher meat diet adherence also trended to fail EEN induction therapy (lack/loss of response, $p = 0.075$). Meat diet adherence was not associated with disease flare (need for GCS) in male patients or with any clinical outcomes in female patients. Failure numbers were insufficient to control for baseline disease activity. Among the subset of 48 patients with PGA scores available at both baseline and 6 months, rMED score was associated with a decreased likelihood of PGA improvement and a smaller reduction in PGA from baseline to six months ($\rho = -0.4406$, $p < 0.01$; $p < 0.05$, respectively; Figure 2D,F) but was not associated with our defined EEN clinical outcomes (e.g., flare or need for anti-TNF). Only 5 of 48 patients (10%) showed no improvement in PGA over 6 months. rMED score also trended lower in males ($p = 0.068$), who also tended ($p = 0.056$) to have less severe disease at baseline. Numbers of patients that had PGA available at both baseline and 6 months were insufficient to perform sub-analysis by sex.




Figure 2. Dietary associations with baseline and long-term clinical outcomes. (A): Mature diet adherence was negatively associated with SES-CD score at baseline in females. ($\rho = -0.4556$, $p < 0.05$, $n = 34$ with relevant data available). (B): Mature diet adherence was negatively associated with baseline FCP in males ($\rho = -0.4556$, $p < 0.05$, $n = 18$). (C,D): rMED score was negatively associated

with SES-CD score at baseline and showed a smaller reduction in PGA in females. ($\rho = -0.42$, $p < 0.05$, $n = 34$, $\rho = -0.4406$, $p < 0.01$, $n = 36$, respectively). (E): Higher meat adherence was associated with a loss of response to EEN in males ($p < 0.05$). (F): A higher rMED score was associated with a decreased likelihood to show improvement in PGA from baseline to six months. (G): Lower adherence to a pre-packaged diet was associated with earlier development of disease flare in males, $p < 0.05$, $n = 59$. (H): Lower adherence to a mature diet was associated with an earlier need for anti-TNF, $p = 0.086$, $n = 76$. * = $p < 0.05$, tertile 1 = lowest adherence, tertile 3 = highest.

Surprisingly, a pre-packaged diet was associated with protection or delay of disease flare in male patients. Males in the lowest tertile for pre-packaged diet adherence experienced earlier disease flares [$p < 0.05$, (relative risk) RR = 0.392, 95% CI 0.186–0.827; Figure 2G], but this might reflect the association of the pre-packaged dietary pattern with rMED (Figure S1); pre-packaged diet adherence did not predict EEN failure or a need for anti-TNF in males and was not associated with clinical outcomes in female patients. For patients with successful EEN induction, a higher mature diet adherence was associated with a delayed need for anti-TNF ($p = 0.086$, RR = 0.634; 95% CI 0.377–1.067, Figure 2H). Neither vegetarian diet adherence nor rMED scores were associated with our defined EEN treatment outcomes, disease flare timing, or need for anti-TNF. To illustrate the differences in dietary intake between tertiles of adherence for each dietary pattern, Supplemental Figures S3 and S4 compare differences in daily servings of food groups.

3.4. Baseline and 6-Month Microbial Composition and Diversity Are Associated with Pre-Diagnosis Diet

After identifying dietary links with treatment outcomes, we assessed for associations between fecal microbiota and diet. Patterns of microbiota, as identified by 16SrRNA sequencing and summarized by PCA, were evaluated for correlation with dietary pattern adherence and rMED scores. Mature diet adherence and rMED scores were found to correlate with patient baseline intestinal microbiota patterns ($\rho = -0.4266$, $p < 0.05$; $\rho = -0.4415$, $p < 0.01$, respectively).

The microbiota amplicon sequences variants (ASVs) most strongly represented in the correlation with mature diet and rMED scores at baseline (largest factor loadings) were three Faecalibacterium ASVs, two Blautia, Ruminococcus gnavus group ASVs, Ruminococcus torques, Ruminococcus gauvreauii groups, Coprococcus, and Ruminococcaceae UCG-002. Among these, one Blautia and one Faecalibacterium ASV were associated with higher mature diet adherence ($\rho = 0.3989$, $p < 0.05$; $\rho = 0.4801$, $p < 0.01$, respectively), while lower mature diet adherence was associated with an increased Ruminococcus gnavus group ASV ($\rho = -0.4179$, $p < 0.05$, Figure 3A–C). The second Blautia and Faecalibacterium ASVs were not significantly associated with mature diet adherence (Figure 3A–C). Higher rMED scores were associated with increased Blautia (ASV1: $\rho = 0.4004$, $p < 0.05$; ASV2: $\rho = 0.4635$, $p < 0.01$, Figure 3D). Two Faecalibacterium ASVs were approaching significance (ASV1) and significantly (ASV2) associated with higher rMED scores (ASV1: $\rho = 0.3273$, $p = 0.0514$; ASV2: $\rho = 0.4322$, $p < 0.01$, Figure 3E). The Ruminococcus gnavus group ASV was negatively associated with rMED scores ($\rho = -0.4444$, $p < 0.01$, Figure 3F). Ruminococcus torques, Coprococcus, and Ruminococcaceae UCG-002 were not associated with any of the dietary patterns or rMED scores.




Figure 3. Dietary patterns and rMED score are associated with baseline microbial abundances, microbial diversity, and richness. (A,B): Baseline *Blautia* ASV1 and *Faecalibacterium* ASV2 relative abundances were positively associated with mature diet adherence ($\rho = 0.3989$, $p < 0.05$, $n = 35$; $\rho = 0.4801$, $p < 0.01$, $n = 35$). *Blautia* ASV2 and *Faecalibacterium* ASV1 were not significantly associated ($p > 0.05$). (C): Baseline *Ruminococcus gnavus* group ASV relative abundance was negatively associated with mature diet adherence ($\rho = -0.4179$, $p < 0.05$, $n = 35$). (D): Baseline *Blautia* relative abundances were positively associated with rMED score (ASV1 $\rho = 0.4004$, $p < 0.05$, $n = 36$; ASV2 $\rho = 0.4635$, $p < 0.01$, $n = 36$). (E): *Faecalibacterium* ASV1 baseline relative abundance was positively associated with rMED score at baseline ($\rho = 0.3273$, $p = 0.0514$, $n = 36$), ASV2 baseline relative abundance was positively associated with rMED score ($\rho = 0.4322$, $p < 0.01$, $n = 36$). (F): *Ruminococcus gnavus* group ASV baseline relative abundance was negatively associated with rMED score ($\rho = -0.4444$, $p < 0.01$, $n = 36$). (G–I): Simpson diversity at baseline was not associated with mature diet adherence, but mature diet adherence was associated with increased Shannon diversity and richness (Chao1) at baseline ($\rho = 0.2787$, $p > 0.05$, $n = 35$; $\rho = 0.3989$, $p < 0.05$, $n = 35$; $\rho = 0.4968$, $p < 0.01$, $n = 35$). (J–L): Increased vegetarian diet adherence was associated with increased Simpson and trending Shannon microbial diversity, but not richness (Chao1), at baseline ($\rho = 0.3583$, $p < 0.05$, $n = 35$; $\rho = 0.3323$, $p = 0.0508$, $n = 35$; $\rho = 0.1347$, $p > 0.05$, $n = 35$). (M–O): rMED scores were positively associated with Simpson and Shannon diversity as well as microbial richness (Chao1) at baseline ($\rho = 0.3302$, $p < 0.05$, $n = 36$; $\rho = 0.4454$, $p < 0.01$, $n = 36$; $\rho = 0.5218$, $p < 0.01$, $n = 36$).

Higher mature diet adherence was associated with increased Shannon (but not Simpson) diversity and richness (Chao1) at baseline ($\rho = 0.3989, p < 0.05$; $\rho = 0.3952, p < 0.05$; $\rho = 0.4968, p < 0.01$, respectively; $n = 35$ with available microbiome data, Figure 3G–I). Higher vegetarian diet adherence was associated with increased microbial Simpson diversity and increased Shannon diversity ($\rho = 0.3583, p < 0.05$; $\rho = 0.3323, p = 0.0508$, respectively; $n = 35$), but was not significantly associated with richness (Chao1, $\rho = 0.1347, p > 0.05, n = 35$, Figure 3J–L). rMED scores were positively associated with Simpson and Shannon diversity as well as microbial richness (Chao1) at baseline ($\rho = 0.3302, p < 0.05$; $\rho = 0.4454, p < 0.01, n = 36$; $\rho = 0.5218, p < 0.01$, respectively; $n = 36$, Figure 3M–O).

Higher mature diet adherence was also associated with increased Simpson diversity, trending Shannon diversity, and richness (Chao1) at six months ($\rho = 0.4675, p < 0.05$; $\rho = 0.4234, p = 0.0559$; $\rho = 0.3891, p = 0.0813$, respectively, Figure 4A–C). Pre-packaged diet adherence was inversely associated with Shannon diversity (but not Simpson) and richness at six months ($\rho = 0.3984, p < 0.05$; $\rho = 0.5059, p < 0.01$, respectively, Figure 4D–F). Meat diet adherence was not associated with any significant differences in microbial diversity.

3.5. Lower Baseline Microbial Diversity Was Associated with Earlier Disease Flare

There were no significant differences in baseline microbiota patterns or diversity/richness scores in patients that failed EEN compared to responders (loss or lack of response; failures $n = 4$, responders $n = 27$; the five patients who started anti-TNF therapy concomitant with EEN were not included). Among those who responded to EEN ($n = 27$ with baseline stool available), lower Simpson and Shannon microbial diversity at baseline was associated with earlier disease flare (HR:0.00044, $p < 0.05$, 95%CI 0–0.819; HR = 0.403, $p = 0.05$, 95%CI 0.162–1.002, Figure 5). Richness (Chao1) was not associated with disease flare. For graphical purposes, tertiles of microbial diversity are shown in Figure 5; continuous diversity was used for analyses.

3.6. Additional Sex-Specific Findings

We identified several sex-specific correlations between diet, microbes, and clinical outcomes. Adherence to diet patterns (Figure S5A,B) was significantly different: males showed a higher adherence to the mature diet (median -0.13 , IQR 1.38; females median -0.15 , IQR 1.06; $p < 0.05$) with higher rMED scores (males median 17, IQR 14.5–19; females median 15, IQR 13–18; $p = 0.068$). Females had a significantly higher PGA (disease severity) at baseline ($p < 0.05$, Figure S6A). There was no significant difference in PGA at six months between males and females (Figure S6B). Baseline SES-CD score and FCP showed sex-specific correlations with dietary patterns (Figure 2E), and as described above—increased adherence to the meat dietary pattern was associated with lack of clinical response to EEN only in males ($p < 0.05$, Figure 2E). Additionally, only among males was higher pre-packaged diet pattern adherence associated with delayed disease flare ($p < 0.05$, Figure 2G). In females, significant differences in diet were associated with disease location: mature diet adherence was higher for Paris L1 (median 0.23, IQR 1.42; Paris L2/L3 0.036, IQR 1.22, $p < 0.01$), and pre-packaged diet adherence was lower for Paris L1 (median -0.11 , IQR 0.89; Paris L2/L3 -0.037 , IQR 0.57, $p < 0.01$, Figure S5C,D).




Figure 4. Pre-diagnosis diet is associated with microbial diversity at 6 months. (A–C): Increased mature diet adherence was associated with increased Simpson diversity, increased Shannon diversity, and an increase in richness at 6 months ($\rho = 0.4234$, $p = 0.0559$, $n = 24$; $\rho = 0.4675$, $p < 0.05$, $n = 24$; $\rho = 0.3891$, $p = 0.0813$, $n = 24$). (D–F): Pre-packaged diet adherence was not associated with Simpson diversity at 6 months ($\rho = -0.2945$, $p > 0.05$) but was inversely associated with Shannon diversity and richness at 6 months ($\rho = 0.3984$, $p < 0.05$, $n = 23$; $\rho = 0.5059$, $p < 0.01$, $n = 23$).




Figure 5. Lower baseline microbial diversity is associated with decreased time to disease flare. A lower Simpson diversity at baseline was associated with decreased time until disease flare requiring GCS; tertiles are shown for illustrative purposes; $n = 29$, with three disease flares. Tertile 1 = lowest diversity, tertile 3 = highest.

4. Discussion

Prospective data and stool samples collected from children newly diagnosed with CD who received EEN as primary induction therapy allowed us to investigate if pre-diagnosis dietary patterns could predict EEN treatment response and outcomes over 18 months of follow-up. In addition, we assessed for variations in intestinal microbes with diet and treatment response. We found that pre-diagnosis diet was indeed associated with some important clinical outcomes, including response to EEN, disease flare, and a need for therapy escalation to anti-TNF. As summarized in Figure 6, we also identified diet–microbial diversity and microbial diversity–treatment/outcome associations, suggesting that gut microbiota (as established by diet) may indeed mediate responses to EEN.

Our identified dietary patterns were named vegetarian, meat, pre-packaged, and mature (derived from detailed patient FFQ data) and are consistent with other Canadian pediatric population-derived dietary patterns [35], as well as dietary patterns identified by meta-analysis in other populations [36].

Our finding of an inverse correlation between baseline disease severity, mature adherence, and rMED scores is supportive of other findings suggesting a protective effect of the MED in IBD [9]. This is further supported by our identified association between increased mature diet adherence and a delayed need for anti-TNF. Although not associated with our defined EEN outcomes of interest, rMED was associated with a decreased likelihood of PGA improvement and a smaller reduction in PGA from baseline to six months. Analysis of this significance is complicated, as males had lower rMED scores and lower baseline disease severity. Additionally, two-thirds of our population was male, but there were insufficient numbers of patients with both baseline and 6-month PGAs available to perform sub-analysis by sex, as very few patients (5/48, 10%) did not see an improvement in PGA. It remains possible that there is a relationship between a MED and less improvement of long-term outcomes with EEN, apart from a need for anti-TNF or GCS, while a MED remains protective in IBD prior to EEN administration. Given that less than half of our patients (48/103) had data available for long-term PGA analysis, this relationship requires further investigation.

Our observed association between increased meat diet adherence and EEN induction failure supports reports linking increased meat consumption to more active disease [8], possibly through meat-related intestinal microbiome alterations, as shown in IBD animal models [37,38]. Higher microbial diversity associated with our identified vegetarian diet (low in meat consumption) also suggests a role for microbial mediation, as decreased α -diversity is a hallmark of IBD [6].




Figure 6. Linking pre-diagnosis diet to treatment outcomes through fecal microbiota. Our study revealed multiple links between pre-diagnosis diet, microbes, and patient outcomes, which are summarized in this figure. Mature and vegetarian diets and rMED score were positively associated with baseline microbial diversity, while pre-packaged diet was negatively associated with six-month diversity. Increased baseline diversity was associated with prolonged survival until disease flare. A decreased pre-packaged diet adherence and increased meat diet adherence were associated with decreased time until disease flare and lack of EEN response, respectively. Finally, increased rMED score was associated with a worse six-month PGA and a decreased likelihood for PGA improvement from baseline.

Surprisingly, a higher pre-packaged diet adherence was associated with delayed disease flare in males. This could reflect protection from the decreased consumption of lean red and processed meat found with this diet or the consumption of high-fiber cereals (increased in this dietary pattern), resulting in increased protective fiber intake [39]. Pre-packaged adherence also trended towards a positive association with rMED scores, suggesting that this dietary pattern captures multiple complex relationships, including a more Mediterranean style of eating. PCA to obtain data-derived dietary patterns captures actual consumption patterns, which can result in clustering of seemingly counteracting food products. Although this complicates the identification of single culprit or savior foods, it accurately captures the complexity of patients' diets, which contain a diversity of so-called healthful and ultra-processed foods. Holistic analysis of patients' diets in observational studies, as we have performed here, can provide clues for future experimental studies to identify causal relationships. Taking this into account, it is important to remember that our findings cannot directly support or disprove a causative role for diet in mediating IBD pathogenesis.

Decreased microbial diversity has been previously associated with increased disease severity in pediatric IBD [40]. Our findings that a lower baseline microbial diversity was associated with earlier disease flare (Figure 5) illustrate that microbial changes could precede a clinically detectable need for GCSs. These findings support the role of microbial

mediators in the pathogenesis of IBD and can therefore provide further targets in the development of novel microbe-altering therapies.

Mature diet adherence was associated with increased microbial diversity and richness at baseline and six months, as well as a trending association with delayed need for anti-TNF (Figure 2H) among those with successful EEN induction. Increased microbial diversity has been found to predict treatment outcomes with anti-TNF in pediatric IBD [40]. Furthermore, suggesting a microbial mediator for these dietary associations, mature diet adherence was associated with a decrease in *Ruminococcus gnavus* group ASVs, which are strict anaerobic gram-positive bacteria that have been associated with increased disease severity in pediatric IBD [41]. Mature diet adherence and rMED scores were positively associated with baseline *Blautia* and *Faecalibacterium* ASVs. Some strains of *Faecalibacterium* are thought to be beneficial due to their ability to produce butyrate, which has been associated with lower intestinal inflammation and greater intestinal barrier integrity [42,43]. Increased dietary intake of fish, nuts, fruits, vegetables, and cereals (similar to a MED) are associated with higher abundance of *F. prausnitzii* [43]. Increasing fruit and vegetable intake is recommended in CD to reduce bacterial mucin metabolism and increase short-chain fatty acid (SCFA) production through microbial fiber fermentation [39]. Increased fruit and vegetable intake with higher adherence to the mature diet could result in increased dietary fiber, providing a substrate for beneficial commensal microbiota.

Blautia present a more complicated picture—although increased baseline *Blautia* spp. can predict a lower likelihood of remission on EEN [16], Hart et al. found increased *Blautia* in pediatric IBD patients that achieved remission on EEN or GCSs [44]. Additionally, increased *Blautia* has been found in patients that achieved remission with the Crohn disease exclusion diet (CDED) dietary therapy [45]. Characterization to the species and strain levels, along with functional assessment, is likely necessary to clarify their complex relationship with host health.

Sex-specific associations between diet and risk for IBD have been previously identified [7], as well as sex-specific alterations in the microbiome in response to dietary changes [46]. The average age of our cohort was 12.6 years; post/intra-pubertal levels of sex hormones may help explain these associations. As our cohort was predominantly male (59.2%), it is possible that we had increased power to detect significant relationships in males, although some findings were observed in females (e.g., association between “pre-packaged” and “mature” dietary patterns and disease location). These results may also be partly explained by gender/cultural factors, but need to be interpreted with caution due to multiple comparisons and low power. One potential consequence of note: in some cohorts, pediatric patients with ileal CD (L1) have been found more likely to succeed with EEN than those with colonic disease (L2/L3) [47]. Perhaps most significantly, females had more severe disease at baseline, and it is possible that dietary influences on the microbiome are overshadowed by the greater effects of inflammation on the microbiome.

Lastly, although diet after diagnosis and completion of EEN was not evaluated, our identified associations between pre-diagnosis diet and 6-, 12-, and 18-month microbiota (Figure 4) supports either long-term stability of the established microbiome despite a temporary change in diet for EEN therapy (as supported by others) [18] or a correlation between pre-diagnosis and post-EEN diet; this highlights the potential ability for long-term diet to continuously influence host–microbe interactions in lifelong diseases such as IBD.

Limitations

While our study produced multiple interesting associations, these need to be interpreted with caution. Although our FFQ did not provide the granularity to assess micronutrients such as fiber, whole foods are more closely correlated with the microbiome than individual nutrients [5], supporting our investigation of associations between dietary patterns and treatment outcomes with potential mediation by the microbiome. FFQs are prone to over-reporting and biases such as social desirability; our use of kilocalorie adjustment and relative dietary patterns within our population help minimize (but do not eliminate)

these effects. While most of the FFQs were collected close to diagnosis, some were collected several weeks later; patients were asked to fill the FFQs to best reflect their pre-diagnosis diet, but it is possible that pre-diagnosis diet was already impacted by subclinical symptoms. It is important to note that we do not have data on dietary habits after EEN therapy, and we cannot assume that the diet is the same or different; changes in dietary behavior after nutritional therapy have been observed by others [48]. 16S rRNA gene sequencing is limited to genus-level phenotypic characterizations of bacteria and does not assess other components of the intestinal microbiome (e.g., microbial function); therefore, our findings provide only initial insight into relationships with microbiota abundance. Fungi and other gut microbes were not assessed.

Smaller numbers of stool samples sizes reduced our power to identify relationships with microbiota and FCP (especially given the low number of EEN failures) and limited our ability to adjust for baseline disease activity. Short-term treatment response at EEN completion was not routinely collected, so we indirectly assessed treatment failure through the need for additional medications and longer-term outcomes (i.e., six-month visit), similar to outcome assessments in other studies [49]. Furthermore, objective measures of remission (endoscopy or FCP) were not available for most patients, so response to EEN was measured clinically and not by follow-up endoscopic assessment. Longer-term outcomes (e.g., 6 months) were also affected by additional therapies and are not necessarily a direct result of EEN. Although there are consensus guidelines for CD treatment and clinicians in our study specified the reason for each therapy, some subjectivity remains between clinicians and sites in a multi-center study. The very low rate of EEN failures limited the power of our study to identify predictors of negative outcomes. Finally, multiple outcomes and relationships between many variables were assessed, in some cases with small numbers, leading to numerous results with variable statistical significance; although this can increase the risk of type I error, this exploratory study of complex associations provides us with direction for new hypotheses for further investigation. Therefore, many of these results need to be further confirmed in larger studies to best interpret our findings.

5. Conclusions

Multi-center prospective sampling and data collection enabled us to identify dietary predictors of treatment response and long-term outcomes in pediatric patients with CD receiving EEN induction therapy. A mediating role of the microbiome is supported by diet–microbiota and microbiota–clinical outcome associations. For example, a “mature diet” can decrease disease severity by increasing beneficial microbes (such as *Faecalibacterium*). Our findings suggest that baseline microbiota established through long-term diet partly determines therapy response; this may be considered in evaluation for future treatment regimens and development of personalized diets. As shown in Figure 6, further investigations of the complex relationships identified here can allow for more targeted therapies that will better harness diet-microbe-disease interactions.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/nu16071033/s1>, Additional methodology (FFQ kilocalorie adjustments; relative Mediterranean diet; microbiome analysis); Figure S1: Diet pattern associations with rMED Scores; Figure S2: Mature diet adherence is positively associated with age; Figure S3: Food group intake for meat tertiles in males, and mature tertiles in all patients; Figure S4: Food group intakes between pre-packaged tertiles in males and rMED tertiles in all patients; Figure S5: Sex-specific diet differences and associations between diet adherence and disease location; Figure S6: Sex-specific associations with PGA; Table S1: Center of data collections for the EEN-FFQ cohort; Table S2: Stool specimen collection numbers for baseline, 6-month, 12-month, and 18-month timepoints; Table S3: FFQ food groups used for multivariate analysis; Table S4: PC eigenvalues and % of dietary variance explained. References [50–52] are cited in the supplementary materials.

Author Contributions: Conceptualization, S.D., M.J., M.C., J.W., H.Q.H. and E.W.; methodology, S.D., M.J., Z.Z., M.L., R.S., L.R., M.C., J.W., T.D.W., M.G.S. and E.W.; formal analysis, S.D., M.J., Z.Z., M.L., M.A., R.S., L.R., M.G.S. and E.W.; investigation, S.D., M.W.C., A.O., M.S., D.R.M., K.J., J.C.d., W.E.-M., C.D., M.R., P.C.C., T.D.W., H.Q.H., M.G.S., A.M.G. and E.W.; data curation, S.D., M.J., Z.Z., M.L., M.A., L.R., T.D.W., M.G.S., A.M.G. and E.W.; writing—original draft preparation, S.D., M.G.S., A.M.G. and E.W.; writing—review and editing, all authors; supervision, E.W.; project administration, E.W.; funding acquisition, M.G.S., A.M.G. and E.W. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Canadian Institutes of Health Research (CIHR) and the Children with Intestinal and Liver Disorders (CH.I.L.D.) foundation through funding of The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN). SD was funded by the CIHR and the Women & Children’s Health Research Institute (WCHRI). The Wine lab is funded by the CIHR (Grant number 426160) and the IMAGINE Chronic Disease Network. The IMAGINE Network is supported by a grant from the CIHR (Funding Reference Number: 1715-000-001) with funding from several partners.

Institutional Review Board Statement: Ethics approval was obtained at each participating center (University of Alberta Ethics ID#: Pro00042980, approved 16 December 2013).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The 16S raw sequencing data are deposited into the Sequence Read Archive (SRA) of NCBI (<http://www.ncbi.nlm.nih.gov/sra>) under BioProject PRJNAXXXX. Other data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study.

Acknowledgments: We would like to thank the patients and families for participating in this study and the CIDsCaNN coordinators for their assistance in recruiting patients and collecting data.

Conflicts of Interest: S.D., M.J., Z.Z., M.L., M.A., R.S., L.R., M.C., J.W., M.W.C., M.R., and M.G.S. have no conflicts to report. A.O. has served on an advisory board for AbbVie, Janssen, Pfizer, and Eli-Lilly; has received investigator-initiated research support from AbbVie; and has received educational grants from AbbVie and Janssen. M.S. has served as an advisory board member for AbbVie and is a speaker for Janssen and AbbVie. D.R.M. is a co-founder and shareholder of MedBiome Inc. K.J. has served as an advisory board member for AbbVie, Janssen, Amgen, Merck, Viartis, and McKesson Canada; is a member of AbbVie and Janssen Speaker’s bureau; and has received investigator-initiated research support from Janssen. J.C.d.B. served as an advisory board member and speaker for Abbvie, as well as an advisory board member for Janssen, Amgen, and Mylan. W.E.-M. served as an advisory board member and speaker’s panel member for AbbVie. C.D. served as an advisory board member and speaker for AbbVie, Organon, and Janssen. P.C.C. has received consulting fees from AbbVie, Janssen, Ferring, and Merck; honoraria from Abbvie and Amgen; investigator-initiated research support from AbbVie and Janssen; and educational grants from Janssen, Amgen, Takeda, and Viartis. Thomas D. Walters has received grants from AbbVie, Ferring; honoraria from AbbVie and Pfizer; and served as an advisory board member for AbbVie, Janssen, and Pfizer. H.Q.H. served as an advisory board member and speaker for AbbVie. A.M.G. reports consulting fees from AbbVie, Amgen, BristolMyersSquibb, Janssen, Lilly, Merck, and Pfizer; speaker fees from AbbVie, Janssen, and Nestle; and investigator-initiated research support from AbbVie. E.W. reports personal fees from AbbVie, Janssen, Nestle Health Sciences, BioJamp, Pfizer, and Mead Johnson Nutrition. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Kuenzig, M.E.; Fung, S.G.; Marderfeld, L.; Mak, J.W.Y.; Kaplan, G.G.; Ng, S.C.; Wilson, D.C.; Cameron, F.; Henderson, P.; Kotze, P.G.; et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. *Gastroenterology* **2022**, *162*, 1147–1159.e4. [[CrossRef](#)] [[PubMed](#)]
2. Wong, K.; Isaac, D.M.; Wine, E. Growth Delay in Inflammatory Bowel Diseases: Significance, Causes, and Management. *Dig. Dis. Sci.* **2021**, *66*, 954–964. [[CrossRef](#)] [[PubMed](#)]
3. Chang, J.T. Pathophysiology of Inflammatory Bowel Diseases. *N. Engl. J. Med.* **2020**, *383*, 2652–2664. [[CrossRef](#)] [[PubMed](#)]
4. Dijk, S.; Armstrong, H.; Valcheva, R.; Wine, E. Paediatric IBD: The host, diet & microbes in pathogenesis & treatment: A narrative review. *Dig. Med. Res.* **2021**, *4*. [[CrossRef](#)]

5. Johnson, A.J.; Vangay, P.; Al-Ghalith, G.A.; Hillmann, B.M.; Ward, T.L.; Shields-Cutler, R.R.; Kim, A.D.; Shmagel, A.K.; Syed, A.N.; Students, P.M.C. Daily sampling reveals personalized diet-microbiome associations in humans. *Cell Host Microbe* **2019**, *25*, 789–802.e5. [[CrossRef](#)] [[PubMed](#)]
6. Kostic, A.D.; Xavier, R.J.; Gevers, D. The microbiome in inflammatory bowel disease: Current status and the future ahead. *Gastroenterology* **2014**, *146*, 1489–1499. [[CrossRef](#)] [[PubMed](#)]
7. Levine, A.; Boneh, R.S.; Wine, E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gut* **2018**, *67*, 1726–1738. [[CrossRef](#)]
8. Peters, V.; Spooren, C.; Pierik, M.J.; Weersma, R.K.; van Dullemen, H.M.; Festen, E.A.M.; Visschedijk, M.C.; Masclee, A.A.M.; Hendrix, E.M.B.; Almeida, R.J.; et al. Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients. *J. Crohn's Colitis* **2021**, *15*, 1305–1315. [[CrossRef](#)]
9. Chicco, F.; Magri, S.; Cingolani, A.; Paduano, D.; Pesenti, M.; Zara, F.; Tumbarello, F.; Urru, E.; Melis, A.; Casula, L.; et al. Multidimensional Impact of Mediterranean Diet on IBD Patients. *Inflamm. Bowel Dis.* **2021**, *27*, 1–9. [[CrossRef](#)]
10. Lewis, J.D.; Sandler, R.S.; Brotherton, C.; Brensinger, C.; Li, H.; Kappelman, M.D.; Daniel, S.G.; Bittinger, K.; Albenberg, L.; Valentine, J.F.; et al. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. *Gastroenterology* **2021**, *161*, 837–852.e9. [[CrossRef](#)]
11. Ghosh, T.S.; Rampelli, S.; Jeffery, I.B.; Santoro, A.; Neto, M.; Capri, M.; Giampieri, E.; Jennings, A.; Candela, M.; Turrone, S. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: The NU-AGE 1-year dietary intervention across five European countries. *Gut* **2020**, *69*, 1218–1228. [[CrossRef](#)] [[PubMed](#)]
12. van Rheenen, P.F.; Aloï, M.; Assa, A.; Bronsky, J.; Escher, J.C.; Fagerberg, U.L.; Gasparetto, M.; Gerasimidis, K.; Griffiths, A.; Henderson, P.; et al. The Medical Management of Paediatric Crohn's Disease: An ECCO-ESPGHAN Guideline Update. *J. Crohn's Colitis* **2021**, *15*, 171–194. [[CrossRef](#)] [[PubMed](#)]
13. Yu, Y.; Chen, K.-C.; Chen, J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: A meta-analysis. *World J. Pediatr.* **2019**, *15*, 26–36. [[CrossRef](#)] [[PubMed](#)]
14. Levine, A.; Wine, E. Effects of enteral nutrition on Crohn's disease: Clues to the impact of diet on disease pathogenesis. *Inflamm. Bowel Dis.* **2013**, *19*, 1322–1329. [[CrossRef](#)] [[PubMed](#)]
15. Lawley, M.; Wu, J.W.; Navas-López, V.M.; Huynh, H.Q.; Carroll, M.W.; Chen, M.; Medvedev, P.; Day, A.S.; Hussey, S.; Sigall-Boneh, R. Global variation in use of enteral nutrition for pediatric Crohn disease. *J. Pediatr. Gastroenterol. Nutr.* **2018**, *67*, e22–e29. [[CrossRef](#)] [[PubMed](#)]
16. Diederer, K.; Li, J.V.; Donachie, G.E.; de Meij, T.G.; de Waart, D.R.; Hakvoort, T.B.; Kindermann, A.; Wagner, J.; Auyeung, V.; Te Velde, A.A. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease. *Sci. Rep.* **2020**, *10*, 18879. [[CrossRef](#)] [[PubMed](#)]
17. Griffin, N.W.; Ahern, P.P.; Cheng, J.; Heath, A.C.; Ilkayeva, O.; Newgard, C.B.; Fontana, L.; Gordon, J.I. Prior dietary practices and connections to a human gut microbial metacommunity alter responses to diet interventions. *Cell Host Microbe* **2017**, *21*, 84–96. [[CrossRef](#)]
18. Faith, J.J.; Guruge, J.L.; Charbonneau, M.; Subramanian, S.; Seedorf, H.; Goodman, A.L.; Clemente, J.C.; Knight, R.; Heath, A.C.; Leibel, R.L. The long-term stability of the human gut microbiota. *Science* **2013**, *341*, 1237439. [[CrossRef](#)]
19. Berry, S.E.; Valdes, A.M.; Drew, D.A.; Asnicar, F.; Mazidi, M.; Wolf, J.; Capdevila, J.; Hadjigeorgiou, G.; Davies, R.; Al Khatib, H. Human postprandial responses to food and potential for precision nutrition. *Nat. Med.* **2020**, *26*, 964–973. [[CrossRef](#)]
20. Dhaliwal, J.; Walters, T.; Mack, D.; Huynh, H.; Jacobson, K.; Otley, A.; Debruyne, J.; El-Matary, W.; Deslandres, C.; Sherlock, M. Phenotypic variation in paediatric inflammatory bowel disease by age: A multicentre prospective inception cohort study of the Canadian children IBD network. *J. Crohn's Colitis* **2020**, *14*, 445–454. [[CrossRef](#)]
21. Harris, P.A.; Taylor, R.; Minor, B.L.; Elliott, V.; Fernandez, M.; O'Neal, L.; McLeod, L.; Delacqua, G.; Delacqua, F.; Kirby, J. The REDCap consortium: Building an international community of software platform partners. *J. Biomed. Inform.* **2019**, *95*, 103208. [[CrossRef](#)] [[PubMed](#)]
22. Levine, A.; Griffiths, A.; Markowitz, J.; Wilson, D.C.; Turner, D.; Russell, R.K.; Fell, J.; Ruemmele, F.M.; Walters, T.; Sherlock, M. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. *Inflamm. Bowel Dis.* **2011**, *17*, 1314–1321. [[CrossRef](#)] [[PubMed](#)]
23. Grant, A.; Crane, M.; Laupacis, A.; Griffiths, A.; Burnett, D.; Hood, A.; Kluthe, C.; Maghera, M.; Mann, M.; Mansi, M. Engaging patients and caregivers in research for pediatric inflammatory bowel disease: Top 10 research priorities. *J. Pediatr. Gastroenterol. Nutr.* **2019**, *69*, 317–323. [[CrossRef](#)] [[PubMed](#)]
24. Levine, A.; Koletzko, S.; Turner, D.; Escher, J.C.; Cucchiara, S.; De Ridder, L.; Kolho, K.-L.; Veres, G.; Russell, R.K.; Paerregaard, A. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J. Pediatr. Gastroenterol. Nutr.* **2014**, *58*, 795–806. [[CrossRef](#)] [[PubMed](#)]
25. Shatenstein, B.; Amre, D.; Jabbour, M.; Feguery, H. Examining the relative validity of an adult food frequency questionnaire in children and adolescents. *J. Pediatr. Gastroenterol. Nutr.* **2010**, *51*, 645–652. [[CrossRef](#)] [[PubMed](#)]
26. Buckland, G.; González, C.A.; Agudo, A.; Vilardell, M.; Berenguer, A.; Amiano, P.; Ardanaz, E.; Arriola, L.; Barricarte, A.; Basterretxea, M. Adherence to the Mediterranean diet and risk of coronary heart disease in the Spanish EPIC Cohort Study. *Am. J. Epidemiol.* **2009**, *170*, 1518–1529. [[CrossRef](#)] [[PubMed](#)]

27. Trichopoulou, A.; Costacou, T.; Bamia, C.; Trichopoulos, D. Adherence to a Mediterranean diet and survival in a Greek population. *N. Engl. J. Med.* **2003**, *348*, 2599–2608. [[CrossRef](#)] [[PubMed](#)]
28. Turner, D.; Levine, A.; Walters, T.D.; Focht, G.; Otley, A.; López, V.N.; Koletzko, S.; Baldassano, R.; Mack, D.; Hyams, J.; et al. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease? *J. Pediatr. Gastroenterol. Nutr.* **2017**, *64*, 254–260. [[CrossRef](#)] [[PubMed](#)]
29. Daperno, M.; D’Haens, G.; Van Assche, G.; Baert, F.; Bulois, P.; Maunoury, V.; Sostegni, R.; Rocca, R.; Pera, A.; Gevers, A. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD. *Gastrointest. Endosc.* **2004**, *60*, 505–512. [[CrossRef](#)]
30. Stearns, J.C.; Davidson, C.J.; McKeon, S.; Whelan, F.J.; Fontes, M.E.; Schryvers, A.B.; Bowdish, D.M.; Kellner, J.D.; Surette, M.G. Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age. *ISME J.* **2015**, *9*, 1246–1259. [[CrossRef](#)]
31. Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith, G.A.; Alexander, H.; Alm, E.J.; Arumugam, M.; Asnicar, F.; et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* **2019**, *37*, 852–857. [[CrossRef](#)] [[PubMed](#)]
32. Callahan, B.J.; McMurdie, P.J.; Rosen, M.J.; Han, A.W.; Johnson, A.J.A.; Holmes, S.P. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* **2016**, *13*, 581–583. [[CrossRef](#)] [[PubMed](#)]
33. Turner, D.; Griffiths, A.M.; Walters, T.D.; Seah, T.; Markowitz, J.; Pfefferkorn, M.; Keljo, D.; Waxman, J.; Otley, A.; LeLeiko, N.S. Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. *Inflamm. Bowel Dis.* **2012**, *18*, 55–62. [[CrossRef](#)]
34. StataCorp. *Stata Statistical Software: Release 14*; StataCorp: College Station, TX, USA, 2015.
35. Movassagh, E.Z.; Baxter-Jones, A.D.; Kontulainen, S.; Whiting, S.J.; Vatanparast, H. Tracking dietary patterns over 20 years from childhood through adolescence into young adulthood: The Saskatchewan Pediatric Bone Mineral Accrual Study. *Nutrients* **2017**, *9*, 990. [[CrossRef](#)] [[PubMed](#)]
36. Del-Ponte, B.; Quinte, G.C.; Cruz, S.; Grellert, M.; Santos, I.S. Dietary patterns and attention deficit/hyperactivity disorder (ADHD): A systematic review and meta-analysis. *J. Affect. Disord.* **2019**, *252*, 160–173. [[CrossRef](#)] [[PubMed](#)]
37. Devkota, S.; Wang, Y.; Musch, M.W.; Leone, V.; Fehlner-Peach, H.; Nadimpalli, A.; Antonopoulos, D.A.; Jabri, B.; Chang, E.B. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10^{−/−} mice. *Nature* **2012**, *487*, 104–108. [[CrossRef](#)] [[PubMed](#)]
38. David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.B.; Button, J.E.; Wolfe, B.E.; Ling, A.V.; Devlin, A.S.; Varma, Y.; Fischbach, M.A. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* **2014**, *505*, 559–563. [[CrossRef](#)] [[PubMed](#)]
39. Levine, A.; Rhodes, J.M.; Lindsay, J.O.; Abreu, M.T.; Kamm, M.A.; Gibson, P.R.; Gasche, C.; Silverberg, M.S.; Mahadevan, U.; Boneh, R.S.; et al. Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. *Clin. Gastroenterol. Hepatol.* **2020**, *18*, 1381–1392. [[CrossRef](#)] [[PubMed](#)]
40. Papa, E.; Docktor, M.; Smillie, C.; Weber, S.; Preheim, S.P.; Gevers, D.; Giannoukos, G.; Ciulla, D.; Tabbaa, D.; Ingram, J. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. *PLoS ONE* **2012**, *7*, e39242. [[CrossRef](#)]
41. Olbjørn, C.; Småstuen, M.C.; Thiis-Evensen, E.; Nakstad, B.; Vatn, M.H.; Jahnsen, J.; Ricanek, P.; Vatn, S.; Moen, A.E.; Tannæs, T.M. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease—associations with disease phenotype, treatment, and outcome. *Clin. Exp. Gastroenterol.* **2019**, *12*, 37. [[CrossRef](#)]
42. Zhou, L.; Zhang, M.; Wang, Y.; Dorfman, R.G.; Liu, H.; Yu, T.; Chen, X.; Tang, D.; Xu, L.; Yin, Y. Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. *Inflamm. Bowel Dis.* **2018**, *24*, 1926–1940. [[CrossRef](#)] [[PubMed](#)]
43. Bolte, L.A.; Vich Vila, A.; Imhann, F.; Collij, V.; Gacesa, R.; Peters, V.; Wijmenga, C.; Kurilshikov, A.; Campmans-Kuijpers, M.J.E.; Fu, J.; et al. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. *Gut* **2021**, *70*, 1287–1298. [[CrossRef](#)] [[PubMed](#)]
44. Hart, L.; Farbod, Y.; Szamosi, J.C.; Yamamoto, M.; Britz-McKibbin, P.; Halgren, C.; Zachos, M.; Pai, N. Effect of Exclusive Enteral Nutrition and Corticosteroid Induction Therapy on the Gut Microbiota of Pediatric Patients with Inflammatory Bowel Disease. *Nutrients* **2020**, *12*, 1691. [[CrossRef](#)] [[PubMed](#)]
45. Levine, A.; Wine, E.; Assa, A.; Boneh, R.S.; Shaoul, R.; Kori, M.; Cohen, S.; Peleg, S.; Shamaly, H.; On, A. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. *Gastroenterology* **2019**, *157*, 440–450.e8. [[CrossRef](#)] [[PubMed](#)]
46. Bolnick, D.I.; Snowberg, L.K.; Hirsch, P.E.; Lauber, C.L.; Org, E.; Parks, B.; Lusic, A.J.; Knight, R.; Caporaso, J.G.; Svanbäck, R. Individual diet has sex-dependent effects on vertebrate gut microbiota. *Nat. Commun.* **2014**, *5*, 4500. [[CrossRef](#)]
47. de Bie, C.; Kindermann, A.; Escher, J. Use of exclusive enteral nutrition in paediatric Crohn’s disease in The Netherlands. *J. Crohn’s Colitis* **2013**, *7*, 263–270. [[CrossRef](#)] [[PubMed](#)]
48. Martín-Masot, R.; Herrador-López, M.; Navas-López, V.M. Dietary Habit Modifications in Paediatric Patients after One Year of Treatment with the Crohn’s Disease Exclusion Diet. *Nutrients* **2023**, *15*, 554. [[CrossRef](#)]
49. Cosnes, J.; Beaugerie, L.; Carbonnel, F.; Gendre, J.P. Smoking cessation and the course of Crohn’s disease: An intervention study. *Gastroenterology* **2001**, *120*, 1093–1099. [[CrossRef](#)]

50. Willett, W.C.; Howe, G.R.; Kushi, L.H. Adjustment for total energy intake in epidemiologic studies. *Am. J. Clin. Nutr.* **1997**, *65*, 1220S–1228S. [[CrossRef](#)]
51. Szamosi, J.C.; Forbes, J.D.; Copeland, J.K.; Knox, N.C.; Shekarriz, S.; Rossi, L.; Graham, M.; Bonner, C.; Guttman, D.S.; Van Domselaar, G. Assessment of inter-laboratory variation in the characterization and analysis of the mucosal microbiota in Crohn's disease and ulcerative colitis. *Front. Microbiol.* **2020**, *11*, 2028. [[CrossRef](#)]
52. Wang, Q.; Garrity, G.M.; Tiedje, J.M.; Cole, J.R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl. Environ. Microbiol.* **2007**, *73*, 5261–5267. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.